Exosome-derived circCCAR1 promotes CD8+T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma

被引:149
作者
Hu, Zongqiang [1 ,2 ]
Chen, Gang [1 ,2 ]
Zhao, Yingpeng [1 ,2 ]
Gao, Hongqiang [1 ,2 ]
Li, Laibang [1 ,2 ]
Yin, Yanfeng [1 ,2 ]
Jiang, Jie [1 ,2 ]
Wang, Li [1 ,2 ]
Mang, Yuanyi [1 ,2 ]
Gao, Yang [1 ,2 ]
Zhang, Shengning [1 ,2 ]
Ran, Jianghua [1 ,2 ]
Li, Li [1 ,2 ]
机构
[1] Kunming Med Univ, Dept Hepatopancreato Biliary Surg, Peoples Hosp Kunming City 1, 1228 Beijing Rd, Kunming 650032, Yunnan, Peoples R China
[2] Kunming Med Univ, Calmette Affiliated Hosp, 1228 Beijing Rd, Kunming 650032, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
circRNA; CCAR1; Hepatocellular carcinoma; Exosome; Anti-PD1; CELL; REGULATOR; CIRCRNA; RNA;
D O I
10.1186/s12943-023-01759-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundCircular RNAs (circRNAs) can be encapsulated into exosomes to participate in intercellular communication, affecting the malignant progression of a variety of tumors. Dysfunction of CD8 + T cells is the main factor in immune escape from hepatocellular carcinoma (HCC). Nevertheless, the effect of exosome-derived circRNAs on CD8 + T-cell dysfunction needs further exploration.MethodsThe effect of circCCAR1 on the tumorigenesis and metastasis of HCC was assessed by in vitro and in vivo functional experiments. The function of circCCAR1 in CD8 + T-cell dysfunction was measured by enzyme-linked immunosorbent assay (ELISA), western blotting and flow cytometry. Chromatin immunoprecipitation, biotinylated RNA pull-down, RNA immunoprecipitation, and MS2 pull-down assays were used to the exploration of mechanism. A mouse model with reconstituted human immune system components (huNSG mice) was constructed to explore the role of exosomal circCCAR1 in the resistance to anti-PD1 therapy in HCC.ResultsIncreased circCCAR1 levels existed in tumor tissues and exosomes in the plasma of HCC patients, in the culture supernatant and HCC cells. CircCCAR1 accelerated the growth and metastasis of HCC in vitro and in vivo. E1A binding protein p300 (EP300) and eukaryotic translation initiation factor 4A3 (EIF4A3) promoted the biogenesis of circCCAR1, and Wilms tumor 1-associated protein (WTAP)-mediated m6A modification enhanced circCCAR1 stability by binding insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3). CircCCAR1 acted as a sponge for miR-127-5p to upregulate its target WTAP and a feedback loop comprising circCCAR1/miR-127-5p/WTAP axis was formed. CircCCAR1 is secreted by HCC cells in a heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1)-dependent manner. Exosomal circCCAR1 was taken in by CD8 + T cells and caused dysfunction of CD8 + T cells by stabilizing the PD-1 protein. CircCCAR1 promoted resistance to anti-PD1 immunotherapy. Furthermore, increased cell division cycle and apoptosis regulator 1 (CCAR1) induced by EP300 promoted the binding of CCAR1 and beta-catenin protein, which further enhanced the transcription of PD-L1.ConclusionsThe circCCAR1/miR-127-5p/WTAP feedback loop enhances the growth and metastasis of HCC. Exosomal circCCAR1 released by HCC cells contributes to immunosuppression by facilitating CD8 + T-cell dysfunction in HCC. CircCCAR1 induces resistance to anti-PD1 immunotherapy, providing a potential therapeutic strategy for HCC patients.
引用
收藏
页数:21
相关论文
共 48 条
  • [31] NLRP3/IL-1β induced myeloid-derived suppressor cells recruitment and PD-L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma
    Liu, Wenfeng
    Zhang, Feng
    Quan, Bing
    Yao, Fan
    Chen, Rongxin
    Ren, Zhenggang
    Yin, Xin
    MEDCOMM, 2023, 4 (06):
  • [32] Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway
    Wang, Jing
    Yang, Lin
    Wang, Han-xuan
    Cui, Song-ping
    Gao, Ya
    Hu, Bin
    Zhou, Lin
    Lang, Ren
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
  • [33] Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses
    Zhang, Xu-Sheng
    Zhou, Hong-Cai
    Wei, Peng
    Chen, Long
    Ma, Wei-Hu
    Ding, Lin
    Liang, Shi-Cai
    Chen, Ben-Dong
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (12)
  • [34] Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis
    Mengzhou Guo
    Feifei Yuan
    Feng Qi
    Jialei Sun
    Qianwen Rao
    Zhiying Zhao
    Peixin Huang
    Tingting Fang
    Biwei Yang
    Jinglin Xia
    Journal of Translational Medicine, 18
  • [35] Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis
    Guo, Mengzhou
    Yuan, Feifei
    Qi, Feng
    Sun, Jialei
    Rao, Qianwen
    Zhao, Zhiying
    Huang, Peixin
    Fang, Tingting
    Yang, Biwei
    Xia, Jinglin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [36] Overexpressed Tumor Suppressor Exosomal miR-15a-5p in Cancer Cells Inhibits PD1 Expression in CD8+T Cells and Suppresses the Hepatocellular Carcinoma Progression
    Zhang, Hong-Yu
    Liang, Hong-Xia
    Wu, Shu-Huan
    Jiang, He-Qing
    Wang, Qin
    Yu, Zu-Jiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8+ T cells
    Yuan, Yunfeng
    Wang, Lin
    Ge, Di
    Tan, Lijie
    Cao, Benjin
    Fan, Hong
    Xue, Liang
    CANCER LETTERS, 2021, 500 : 98 - 106
  • [38] A Novel TrxR1 Inhibitor Regulates NK and CD8+T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma
    Su, Xiaoxia
    Yin, Hanwei
    Bai, Man
    Liu, Jiayi
    Liu, Runyu
    Zeng, Huihui
    Wen, Jinhua
    JOURNAL OF IMMUNOLOGY, 2023, 210 (05) : 681 - 695
  • [39] Synergistic upregulation of PD-L1 in tumor cells and CD39 in tumor-infiltrating CD8+ T cells leads to poor prognosis in patients with hepatocellular carcinoma
    Kang, Xi
    Zhao, Sinan
    Lin, Shan
    Li, Jing
    Wang, Shunxiang
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [40] SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy
    Luo, Xiangyuan
    Zhang, Zerui
    Li, Siwen
    Wang, Yijun
    Sun, Mengyu
    Hu, Dian
    Jiang, Junqing
    Wang, Yufei
    Ji, Xiaoyu
    Chen, Xiaoping
    Zhang, Bixiang
    Liang, Huifang
    Li, Yiwei
    Liu, Bifeng
    Xu, Xiao
    Wang, Shuai
    Xu, Shengjun
    Nie, Yongzhan
    Wu, Kaichun
    Fan, Daiming
    Liu, Danfei
    Huang, Wenjie
    Xia, Limin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127